Kiromic BioPharma, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial to evaluate KB-GDT-01, or Deltacel, in combination with an anti-tumor therapy for the treatment of non-small cell lung cancer (NSCLC). Deltacel is the Company's allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cell (GDT) therapy The Company is seeking to address the significant unmet need of applying cell therapy to treat solid malignancies, which comprise 90% of all cancers, including NSCLC.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 USD | 0.00% | -4.44% | +245.98% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+245.98% | 4.64M | |
+17.01% | 123B | |
+13.39% | 107B | |
-6.10% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-12.16% | 16.23B | |
+1.81% | 13.43B | |
+22.49% | 11.32B |
- Stock Market
- Equities
- KRBP Stock
- News Kiromic BioPharma, Inc.
- Kiromic Biopharma, Inc. Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer